Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Technologies Raises $15 Million in Private Financing


PALO ALTO, Calif.--Caliper Technologies here has announced that it has raised $15 million on the completion of its Series D private financing. This amount is in addition to the $5 million Caliper raised in February from a collaborative venture with Dow Chemical. It brings the company's total financing to $20 million.

Caliper calls itself a bioinformation technology company. The firm's proprietary LabChipx technology integrates microfabrication, electronics, software, biology, and chemistry. Among the applications of the company's microfluidic bioprocessor are ultra high-throughput experimentation for drug discovery and development, genomics, and biomedical research.

Participants in the financing included Caliper's current investors--Lombard Odier & Cie, State Farm Insurance, and Venrock Associates--joined by new investors Tredegar Investments and BB BioVentures, among others.

"I'm very pleased with the enthusiasm that Caliper has received from the investment community," commented David Lam, Caliper's president and CEO. "This financing places us in a strong position to continue our investments in technology and business development in order to take advantage of market opportunities in biomedical research, biopharmaceuticals and diagnostics."

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.